Hsbc Holdings PLC Cuts Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Hsbc Holdings PLC reduced its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 3.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,676 shares of the company’s stock after selling 436 shares during the period. Hsbc Holdings PLC’s holdings in Kiniksa Pharmaceuticals International were worth $280,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $33,000. Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $41,000. Wealthquest Corp purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth about $42,000. Finally, Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $61,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $32.89, for a total value of $621,259.21. Following the sale, the chief financial officer directly owned 27,009 shares in the company, valued at $888,326.01. This represents a 41.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 558,403 shares of company stock valued at $18,078,671. Corporate insiders own 53.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, July 9th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 30th. Finally, Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $35.51 on Friday. The company’s 50 day simple moving average is $30.79 and its 200-day simple moving average is $26.38. The firm has a market capitalization of $2.63 billion, a PE ratio of 887.97 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $35.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.